{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-031303","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.341727+00:00","generated_at":"2026-05-25T14:21:52.466092+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise","bullets":["Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).","Cash, equivalents & short-term investments were $176.5M at Dec 31, 2024; plus $65.5M raised in Jan 2025.","Phase 3 LUCIDITY trial of avexitide in PBH recruiting; topline data expected first half 2026.","Appointed Dan Monahan as Chief Commercial Officer to lead commercialization strategy.","R&D expenses fell to $22.9M in Q4 2024 from $44.9M in Q4 2023; SG&A fell to $17.1M from $52.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-031303","json":"https://secwatch.observer/filing/0000950170-25-031303.json","markdown":"https://secwatch.observer/filing/0000950170-25-031303.md","text":"https://secwatch.observer/filing/0000950170-25-031303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/0000950170-25-031303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/amlx-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T14:21:52.466092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}